Drugs with SPC(s)

1. List of Acular Ls drug patents

ACULAR LS Litigations
Can you believe ACULAR LS received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8008338 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2027

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8541463 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(11 months from now)

US9216167 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(11 months from now)

US8946281 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(11 months from now)

US8648107 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(11 months from now)

US8906950 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(11 months from now)

US8377982 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(11 months from now)

US8207215 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(11 months from now)

Do you want to check out ACULAR LS patents from before 2022?

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 30 May, 2003

Treatment: A method of treating or reducing ocular pain and burning/stinging; A method of treating ocular pain and/or enhancing ocular comfort; A method of treating ocular pain; A method of treating or preventin...

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACULAR LS before it's patent expiration?
More Information on Dosage

ACULAR LS family patents

16

United States

2

Canada

2

European Union

2. List of Afinitor drug patents

AFINITOR's oppositions filed in EPO
AFINITOR Litigations
Can you believe AFINITOR received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8436010 NOVARTIS Treatment of solid tumors with rapamycin derivatives
Feb, 2022

(1 year, 3 months ago)

US8778962 NOVARTIS Treatment of solid tumors with rapamycin derivatives
Feb, 2022

(1 year, 3 months ago)

US8410131 NOVARTIS Cancer treatment
Nov, 2025

(2 years from now)

Do you want to check out AFINITOR patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 26, 2023

Drugs and Companies using EVEROLIMUS ingredient

Market Authorisation Date: 30 March, 2009

Treatment: Treatment of advanced hormone receptor positive, her2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole; Treatment of patients with tuberou...

Dosage: TABLET;ORAL

How can I launch a generic of AFINITOR before it's patent expiration?
More Information on Dosage

AFINITOR family patents

14

Norway

14

Japan

12

European Union

10

United States

10

Israel

9

Lithuania

8

Spain

8

Russia

7

Hong Kong

7

China

7

Portugal

6

Denmark

6

Cyprus

6

Slovenia

5

Czech Republic

5

Poland

5

Slovakia

3

Canada

3

Korea, Republic of

3

Mexico

3

Luxembourg

2

United Kingdom

2

Taiwan

1

Brazil

1

New Zealand

1

Australia

1

South Africa

1

Hungary

3. List of Afinitor Disperz drug patents

AFINITOR DISPERZ's oppositions filed in EPO
Can you believe AFINITOR DISPERZ received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778962 NOVARTIS PHARM Treatment of solid tumors with rapamycin derivatives
Feb, 2022

(1 year, 3 months ago)

Do you want to check out AFINITOR DISPERZ patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 10, 2025

Drugs and Companies using EVEROLIMUS ingredient

Market Authorisation Date: 29 August, 2012

Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Adjunctive tr...

Dosage: TABLET, FOR SUSPENSION;ORAL

How can I launch a generic of AFINITOR DISPERZ before it's patent expiration?
More Information on Dosage

AFINITOR DISPERZ family patents

14

Norway

14

Japan

12

European Union

10

United States

10

Israel

9

Lithuania

8

Spain

8

Russia

7

Hong Kong

7

China

7

Portugal

6

Denmark

6

Cyprus

6

Slovenia

5

Czech Republic

5

Poland

5

Slovakia

3

Canada

3

Korea, Republic of

3

Mexico

3

Luxembourg

2

United Kingdom

2

Taiwan

1

Brazil

1

New Zealand

1

Australia

1

South Africa

1

Hungary

4. List of Amzeeq drug patents

Can you believe AMZEEQ received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10213512 JOURNEY Topical tetracycline compositions
Oct, 2030

(7 years from now)

US10517882 JOURNEY Method for healing of an infected acne lesion without scarring
Oct, 2030

(7 years from now)

US10086080 JOURNEY Topical tetracycline compositions
Oct, 2030

(7 years from now)

US10821187 JOURNEY Compositions, gels and foams with rheology modulators and uses thereof
Oct, 2030

(7 years from now)

US10265404 JOURNEY Compositions, gels and foams with rheology modulators and uses thereof
Oct, 2030

(7 years from now)

US8992896 JOURNEY Topical tetracycline compositions
Oct, 2030

(7 years from now)

US10137200 JOURNEY Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Oct, 2030

(7 years from now)

US8945516 JOURNEY Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Oct, 2030

(7 years from now)

US9675700 JOURNEY Topical tetracycline compositions
Oct, 2030

(7 years from now)

Do you want to check out AMZEEQ patents from before 2022?

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 October, 2019

Treatment: Treatment of non-nodular acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of AMZEEQ before it's patent expiration?
More Information on Dosage

AMZEEQ family patents

52

United States

IB

5

IB

5

Canada

2

Israel

2

Australia

1

China

1

Brazil

1

South Africa

1

Mexico

1

United Kingdom

1

European Union

5. List of Aplenzin drug patents

Can you believe APLENZIN received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572935 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

US7662407 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

US7585897 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

US7645802 BAUSCH Bupropion hydrobromide and therapeutic applications
Jun, 2026

(3 years from now)

US7241805 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

US7569610 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

US7649019 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

US7671094 BAUSCH Bupropion hydrobromide and therapeutic applications
Jun, 2026

(3 years from now)

Do you want to check out APLENZIN patents from before 2022?

Drugs and Companies using BUPROPION HYDROBROMIDE ingredient

Market Authorisation Date: 23 April, 2008

Treatment: Treatment of major depressive disorder by dosing at intervals of 24 hours

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of APLENZIN before it's patent expiration?
More Information on Dosage

APLENZIN family patents

24

United States

8

European Union

4

Canada

3

Russia

3

China

3

Japan

3

Korea, Republic of

3

Australia

3

South Africa

2

Nicaragua

2

New Zealand

2

Mexico

2

Costa Rica

2

Ecuador

2

Colombia

1

Hong Kong

1

Ireland

1

Singapore

1

Israel

6. List of Aptiom drug patents

APTIOM's oppositions filed in EPO
Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566244 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate
Oct, 2028

(5 years from now)

US10912781 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate
Oct, 2028

(5 years from now)

US8372431 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate
Apr, 2030

(6 years from now)

Do you want to check out APTIOM patents from before 2022?

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

Market Authorisation Date: 08 November, 2013

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of APTIOM before it's patent expiration?
More Information on Dosage

APTIOM family patents

6

United States

4

Japan

3

Korea, Republic of

3

Portugal

2

Spain

2

European Union

1

Denmark

1

RS

1

Poland

1

Russia

1

China

1

Brazil

1

Canada

1

Ukraine

1

Argentina

1

Croatia

1

Cyprus

1

Mexico

1

Australia

1

Lithuania

1

Slovenia

1

Hungary

7. List of Auvelity drug patents

AUVELITY's oppositions filed in EPO
Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799497 AXSOME Combination of dextromethorphan and bupropion for treating depression
Nov, 2034

(11 years from now)

US10806710 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11298352 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11382874 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11273133 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11147808 AXSOME Method of decreasing the fluctuation index of dextromethorphan
Nov, 2034

(11 years from now)

US11273134 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11253491 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9238032 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(11 years from now)

US11197839 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10780064 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(16 years from now)

US11191739 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10966941 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10894047 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10933034 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11058648 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10874665 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9314462 AXSOME Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11344544 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11426370 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10251879 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11291665 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10966974 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9168234 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9370513 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11096937 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10881657 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10548857 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US10512643 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11234946 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11185515 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10925842 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(16 years from now)

US11419867 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11291638 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10864209 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9375429 AXSOME Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
Nov, 2034

(11 years from now)

US9457025 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(11 years from now)

US10898453 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10881624 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11229640 AXSOME Combination of dextromethorphan and bupropion for treating depression
Nov, 2034

(11 years from now)

US11357744 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10780066 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US10058518 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11524008 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10940124 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(16 years from now)

US11433067 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11524007 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11129826 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11141416 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10596167 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(11 years from now)

US11364233 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10080727 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9486450 AXSOME Hydroxybupropion and related compounds as modulators of drug plasma levels
Nov, 2034

(11 years from now)

US10945973 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9700553 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US10966942 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(16 years from now)

US11253492 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10786469 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11517542 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9205083 AXSOME Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
Nov, 2034

(11 years from now)

US9861595 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US10874664 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10092561 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(11 years from now)

US10894046 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10772850 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10786496 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11497721 AXSOME NA
Nov, 2034

(11 years from now)

US11207281 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11020389 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9700528 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9763932 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11123343 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11478468 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11517543 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9867819 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11311534 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10105361 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US10463634 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US10105327 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9408815 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11213521 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10874663 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9968568 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11090300 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9707191 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11141388 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9278095 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11510918 AXSOME NA
Nov, 2034

(11 years from now)

US10064857 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11426401 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11298351 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10092560 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9198905 AXSOME Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11285146 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11285118 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

Do you want to check out AUVELITY patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Aug 18, 2025

Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient

Market Authorisation Date: 18 August, 2022

Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

AUVELITY family patents

198

United States

15

China

12

Australia

11

Korea, Republic of

10

Japan

9

Canada

9

European Union

8

Singapore

8

New Zealand

8

Israel

3

Brazil

3

Peru

3

Mexico

3

Costa Rica

3

Ecuador

2

Malaysia

2

Chile

2

Colombia

1

Spain

1

Hong Kong

1

Denmark

1

RS

1

Poland

1

Morocco

1

Nicaragua

1

Croatia

1

Portugal

1

Lithuania

1

Slovenia

1

Hungary

8. List of Belbuca drug patents

Can you believe BELBUCA received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9901539 BDSI Transmucosal drug delivery devices for use in chronic pain relief
Dec, 2032

(9 years from now)

Do you want to check out BELBUCA patents from before 2022?

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 October, 2015

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: FILM;BUCCAL

How can I launch a generic of BELBUCA before it's patent expiration?
More Information on Dosage

BELBUCA family patents

7

United States

4

Korea, Republic of

4

Australia

3

Singapore

2

New Zealand

2

China

EA

2

EA

1

Hong Kong

1

Brazil

1

South Africa

1

Canada

1

Ukraine

1

Israel

1

India

1

Mexico

1

Japan

1

European Union

9. List of Bromsite drug patents

Can you believe BROMSITE received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778999 SUN PHARM Non-steroidal anti-inflammatory ophthalmic compositions
Aug, 2029

(6 years from now)

Do you want to check out BROMSITE patents from before 2022?

Drugs and Companies using BROMFENAC SODIUM ingredient

Market Authorisation Date: 08 April, 2016

Treatment: Treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of BROMSITE before it's patent expiration?
More Information on Dosage

BROMSITE family patents

2

United States

1

Spain

1

Canada

1

Portugal

1

Denmark

1

European Union

10. List of Cabometyx drug patents

Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7579473 EXELIXIS INC c-Met modulators and methods of use
Aug, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497284 EXELIXIS INC C-met modulators and method of use
Sep, 2024

(1 year, 3 months from now)

Do you want to check out CABOMETYX patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 17, 2028
New Indication (I) Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of advanced renal cell carcinoma

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's patent expiration?
More Information on Dosage

CABOMETYX family patents

20

United States

13

Japan

9

European Union

7

Australia

6

Spain

5

Hong Kong

4

Croatia

4

Denmark

4

Slovenia

3

Poland

3

Austria

2

Cyprus

2

Canada

2

Portugal

1

Luxembourg

1

Netherlands

1

Hungary

11. List of Caplyta drug patents

Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117867 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
May, 2029

(5 years from now)

US9616061 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
May, 2029

(5 years from now)

US8598119 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
Dec, 2029

(6 years from now)

US10464938 INTRA-CELLULAR Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof
Mar, 2028

(4 years from now)

Do you want to check out CAPLYTA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 20, 2024
New Indication (I) Dec 17, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: 2023-12-21

Market Authorisation Date: 20 December, 2019

Treatment: Treatment of bipolar depression; Treatment of schizophrenia

Dosage: CAPSULE;ORAL

More Information on Dosage

CAPLYTA family patents

24

United States

11

Korea, Republic of

9

Japan

7

Australia

4

China

4

European Union

3

Mexico

2

Canada

1

Spain

1

Hong Kong

1

India

1

Denmark

12. List of Cometriq drug patents

Can you believe COMETRIQ received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7579473 EXELIXIS c-Met modulators and methods of use
Aug, 2026

(3 years from now)

Do you want to check out COMETRIQ patents from before 2022?

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 29 November, 2012

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

COMETRIQ family patents

20

United States

13

Japan

9

European Union

7

Australia

6

Spain

5

Hong Kong

4

Croatia

4

Denmark

4

Slovenia

3

Poland

3

Austria

2

Cyprus

2

Canada

2

Portugal

1

Luxembourg

1

Netherlands

1

Hungary

13. List of Copiktra drug patents

Can you believe COPIKTRA received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8193182 SECURA Substituted isoquinolin-1(2H)-ones, and methods of use thereof
Feb, 2030

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216982 SECURA Certain chemical entities, compositions and methods
Jan, 2029

(5 years from now)

Do you want to check out COPIKTRA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 24, 2023
Orphan Drug Exclusivity (ODE) Sep 24, 2025

Drugs and Companies using DUVELISIB ingredient

NCE-1 date: 2022-09-24

Market Authorisation Date: 24 September, 2018

Treatment: For the treatment of patients with follicular lymphoma (fl); For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)

Dosage: CAPSULE;ORAL

More Information on Dosage

COPIKTRA family patents

25

United States

8

New Zealand

7

European Union

6

China

6

Singapore

5

Russia

5

Ukraine

5

Japan

5

Mexico

4

Malaysia

4

Korea, Republic of

4

Israel

3

Philippines

3

Brazil

3

Canada

3

Australia

3

South Africa

2

Spain

2

Hong Kong

2

Denmark

1

India

1

Poland

1

Croatia

1

San Marino

1

Cyprus

1

Portugal

1

Netherlands

1

Lithuania

1

Slovenia

1

Hungary

14. List of Dexilant drug patents

Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8105626 TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Sep, 2026

(3 years from now)

Do you want to check out DEXILANT patents from before 2022?

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's patent expiration?
More Information on Dosage

DEXILANT family patents

4

Japan

2

Spain

2

Cyprus

2

Portugal

2

Denmark

2

European Union

1

United States

1

China

1

Canada

15. List of Drospirenone drug patents

DROSPIRENONE's oppositions filed in EPO
Can you believe DROSPIRENONE received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11291633 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US9603860 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(8 years from now)

US11413249 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11439598 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11291632 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11504334 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US10179140 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(8 years from now)

US11123299 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US10603281 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(8 years from now)

US10849857 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(8 years from now)

Do you want to check out DROSPIRENONE patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Jun 29, 2025

Drugs and Companies using DROSPIRENONE ingredient

Market Authorisation Date: 29 June, 2022

Treatment: Prevention of pregnancy in females of reproductive age

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage

DROSPIRENONE family patents

19

United States

5

European Union

4

Korea, Republic of

4

Lithuania

4

Hungary

3

Canada

3

Guatemala

3

Mexico

3

Ecuador

2

Spain

2

Denmark

2

RS

2

Poland

2

Brazil

2

Croatia

2

Peru

2

Portugal

2

Slovenia

1

Argentina

EA

1

EA

1

Norway

1

Japan

1

New Zealand

1

Cyprus

1

Chile

1

Australia

1

South Africa

1

Colombia

16. List of Duzallo drug patents

Can you believe DUZALLO received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8546437 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Apr, 2029

(5 years from now)

US8357713 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Dec, 2029

(6 years from now)

US10183012 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Nov, 2028

(5 years from now)

US8283369 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Nov, 2028

(5 years from now)

US8084483 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Aug, 2029

(6 years from now)

Do you want to check out DUZALLO patents from before 2022?

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone

Dosage: TABLET;ORAL

More Information on Dosage

DUZALLO family patents

25

United States

6

China

6

Japan

5

European Union

EA

4

EA

4

New Zealand

4

Korea, Republic of

4

Australia

4

South Africa

3

Hong Kong

3

Brazil

3

Canada

3

Taiwan

3

Mexico

2

Argentina

2

ME

2

Chile

2

Israel

1

Spain

1

Malaysia

1

Denmark

1

RS

1

Poland

1

Ukraine

1

Morocco

1

Singapore

1

Norway

1

Croatia

1

Cyprus

1

Portugal

1

Ecuador

1

Colombia

1

Lithuania

1

Luxembourg

1

Tunisia

1

Slovenia

1

Hungary

17. List of Ezallor Sprinkle drug patents

Can you believe EZALLOR SPRINKLE received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10413543 SUN PHARM Stable multiparticulate pharmaceutical composition of rosuvastatin
Feb, 2036

(12 years from now)

Do you want to check out EZALLOR SPRINKLE patents from before 2022?

Drugs and Companies using ROSUVASTATIN CALCIUM ingredient

Market Authorisation Date: 18 December, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

EZALLOR SPRINKLE family patents

3

United States

2

India

1

European Union

18. List of Fleqsuvy drug patents

Can you believe FLEQSUVY received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446246 AZURITY Suspensions and diluents for metronidazole and baclofen
Sep, 2037

(14 years from now)

US11324696 AZURITY Suspensions and diluents for metronidazole and baclofen
Sep, 2037

(14 years from now)

Do you want to check out FLEQSUVY patents from before 2022?

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 04 February, 2022

Treatment: Indicated for the treatment of spasticity resulting from multiple sclerosis

Dosage: SUSPENSION;ORAL

How can I launch a generic of FLEQSUVY before it's patent expiration?
More Information on Dosage

FLEQSUVY family patents

11

United States

1

China

1

Canada

1

European Union

19. List of Galafold drug patents

Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11241422 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(3 years from now)

US9987263 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(3 years from now)

US9000011 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(3 years from now)

US9480682 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(3 years from now)

US10406143 AMICUS THERAP US Methods for treatment of fabry disease
May, 2027

(3 years from now)

US10383864 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(3 years from now)

Do you want to check out GALAFOLD patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 10, 2023
Orphan Drug Exclusivity (ODE) Aug 10, 2025

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: 2022-08-10

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients

Dosage: CAPSULE;ORAL

How can I launch a generic of GALAFOLD before it's patent expiration?
More Information on Dosage

GALAFOLD family patents

12

United States

5

Japan

5

European Union

3

Spain

3

Hong Kong

2

Poland

2

Slovenia

2

Cyprus

2

Mexico

2

Denmark

2

Hungary

1

Netherlands

1

Canada

1

Portugal

1

Lithuania

1

Luxembourg

1

Australia

20. List of Givlaari drug patents

GIVLAARI Litigations
Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9150605 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Aug, 2025

(2 years from now)

US9708610 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(7 months from now)

Do you want to check out GIVLAARI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 20, 2024
Orphan Drug Exclusivity (ODE) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: 2023-11-21

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

GIVLAARI family patents

119

United States

28

Australia

19

European Union

12

Canada

7

Japan

1

Germany

1

Austria

21. List of Gocovri drug patents

GOCOVRI's oppositions filed in EPO
Can you believe GOCOVRI received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9867791 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

US8741343 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

US11197835 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

US9877933 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

US9867793 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

US9867792 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

Do you want to check out GOCOVRI patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 24, 2024

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 August, 2017

Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and increasing on time with...

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of GOCOVRI before it's patent expiration?
More Information on Dosage

GOCOVRI family patents

26

United States

4

Japan

2

China

2

Canada

2

Mexico

2

Australia

2

European Union

1

Brazil

22. List of Kazano drug patents

Can you believe KAZANO received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(5 years from now)

US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(1 year, 9 months from now)

Do you want to check out KAZANO patents from before 2022?

Drugs and Companies using ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 25 January, 2013

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin; Method of treating diabetes comprising administering alogliptin

Dosage: TABLET;ORAL

How can I launch a generic of KAZANO before it's patent expiration?
More Information on Dosage

KAZANO family patents

11

United States

8

China

3

Japan

2

Argentina

2

Norway

2

Korea, Republic of

2

Israel

2

Taiwan

1

Spain

1

Hong Kong

1

Austria

1

Malaysia

1

Denmark

1

RS

1

Germany

1

Poland

1

Brazil

1

Canada

1

Ukraine

1

Morocco

EA

1

EA

1

New Zealand

1

Croatia

1

Cyprus

1

Portugal

1

Georgia

1

Mexico

1

Australia

1

Costa Rica

1

Netherlands

1

South Africa

1

Luxembourg

1

Slovenia

1

Hungary

1

European Union

23. List of Kloxxado drug patents

Can you believe KLOXXADO received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11135155 HIKMA Liquid naloxone spray
Aug, 2034

(11 years from now)

US10722510 HIKMA Liquid naloxone spray
Aug, 2034

(11 years from now)

US10973814 HIKMA Liquid naloxone spray
Aug, 2034

(11 years from now)

Do you want to check out KLOXXADO patents from before 2022?

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 April, 2021

Treatment: Use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients

Dosage: SPRAY;NASAL

More Information on Dosage

KLOXXADO family patents

13

United States

3

Japan

2

Canada

2

European Union

1

China

1

Morocco

1

Australia

24. List of Leqvio drug patents

LEQVIO's oppositions filed in EPO
Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9708610 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(7 months from now)

US11078485 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(5 months from now)

US8232383 NOVARTIS RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
Feb, 2023

(3 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10266825 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(5 months from now)

Do you want to check out LEQVIO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: 2025-12-22

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascv...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

LEQVIO family patents

639

United States

124

European Union

106

Australia

74

Japan

62

Canada

13

United Kingdom

11

Austria

10

Mexico

9

Germany

6

Spain

6

Denmark

4

China

3

Hong Kong

3

Korea, Republic of

3

Portugal

2

Russia

2

Brazil

2

Norway

2

Cyprus

2

Slovenia

IB

1

IB

1

New Zealand

1

Indonesia

1

Hungary

25. List of Linzess drug patents

LINZESS's oppositions filed in EPO
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7704947 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(7 months from now)

US7304036 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Aug, 2026

(3 years from now)

US7745409 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(7 months from now)

US7371727 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(7 months from now)

US8080526 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(7 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8110553 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(7 months from now)

Do you want to check out LINZESS patents from before 2022?

Drugs and Companies using LINACLOTIDE ingredient

Market Authorisation Date: 30 August, 2012

Treatment: Method of treating irritable bowel syndrome with constipation in adults; Method of treating chronic idiopathic constipation in adult patients.

Dosage: CAPSULE;ORAL

How can I launch a generic of LINZESS before it's patent expiration?
More Information on Dosage

LINZESS family patents

15

United States

5

Japan

5

European Union

4

China

4

Russia

3

Spain

3

Denmark

3

Brazil

3

Singapore

3

Norway

3

New Zealand

3

Korea, Republic of

3

Cyprus

3

Portugal

3

Australia

3

South Africa

3

Slovenia

2

Austria

2

Germany

2

Canada

2

Mexico

2

Luxembourg

1

Hong Kong

1

Israel

1

Netherlands

1

Lithuania

1

Hungary

26. List of Livmarli drug patents

Can you believe LIVMARLI received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11497745 MIRUM NA
Feb, 2040

(16 years from now)

US11229647 MIRUM Methods for treating cholestasis
Feb, 2040

(16 years from now)

Do you want to check out LIVMARLI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 29, 2026
Orphan Drug Exclusivity (ODE) Sep 29, 2028
New Patient Population (NPP) Mar 13, 2026

Drugs and Companies using MARALIXIBAT CHLORIDE ingredient

NCE-1 date: 2025-09-29

Market Authorisation Date: 29 September, 2021

Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)

Dosage: SOLUTION;ORAL

More Information on Dosage

LIVMARLI family patents

13

United States

3

Korea, Republic of

3

China

3

Israel

3

Canada

3

Brazil

3

Japan

3

Australia

3

European Union

27. List of Lorbrena drug patents

Can you believe LORBRENA received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8680111 PFIZER Macrocyclic derivatives for the treatment of diseases
Mar, 2033

(9 years from now)

Do you want to check out LORBRENA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 2, 2023
Orphan Drug Exclusivity (ODE) Mar 3, 2028
New Indication (I) Mar 3, 2024

Drugs and Companies using LORLATINIB ingredient

NCE-1 date: 2022-11-02

Market Authorisation Date: 02 November, 2018

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

LORBRENA family patents

4

United States

2

Japan

2

Lithuania

2

Hungary

1

Uruguay

IB

1

IB

1

Spain

1

Hong Kong

1

Dominican Republic

1

Philippines

1

Moldova, Republic of

1

Denmark

1

RS

1

Poland

1

China

1

Brazil

1

Canada

1

Ukraine

1

Morocco

1

Singapore

1

Argentina

EA

1

EA

1

Norway

1

ME

1

Nicaragua

1

New Zealand

1

Croatia

1

Korea, Republic of

1

Guatemala

1

Cyprus

1

Peru

1

Israel

1

Chile

1

Portugal

1

Taiwan

1

Georgia

1

Mexico

1

Australia

1

Cuba

1

Costa Rica

1

Netherlands

1

South Africa

1

Colombia

1

Luxembourg

1

Tunisia

1

Slovenia

1

European Union

28. List of Mekinist drug patents

Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7378423 NOVARTIS Pyrimidine compound and medical use thereof
May, 2027

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(2 years from now)

Do you want to check out MEKINIST patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 16, 2030
New Product (NP) Mar 16, 2026

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Market Authorisation Date: 16 March, 2023

Treatment: Mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an...

Dosage: SOLUTION;ORAL

More Information on Dosage

MEKINIST family patents

9

United States

6

Japan

3

European Union

2

Spain

2

Denmark

2

RS

2

Poland

2

China

2

Canada

2

Norway

2

Croatia

2

Cyprus

2

Portugal

2

Slovenia

1

Austria

1

Hong Kong

1

Germany

1

Russia

1

Brazil

1

ME

1

New Zealand

1

Korea, Republic of

1

Mexico

1

Australia

1

Netherlands

1

South Africa

1

Luxembourg

1

Hungary

29. List of Mitosol drug patents

Can you believe MITOSOL received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9539241 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
Jan, 2028

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8186511 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
Jul, 2026

(3 years from now)

US9205075 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
Jul, 2026

(3 years from now)

US7806265 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
Feb, 2029

(5 years from now)

US9649428 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
May, 2029

(5 years from now)

Do you want to check out MITOSOL patents from before 2022?

Drugs and Companies using MITOMYCIN ingredient

Market Authorisation Date: 07 February, 2012

Treatment: Mitosol is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. it is intended for topical application to the site of glaucoma filtration surgery

Dosage: FOR SOLUTION;TOPICAL

More Information on Dosage

MITOSOL family patents

6

United States

2

Japan

2

European Union

1

Canada

1

Australia

30. List of Nesina drug patents

Can you believe NESINA received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(1 year, 9 months from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA